CLINICAL LONG-TERM STUDIES FOR TREATMENT OF CHRONIC COMPLICATED URINARY TRACT INFECTIONS: UTILITY AND RECURRENCE AFTER 14-DAY TREATMENT BY CEFDITOREN PIVOXIL

The penetration of tosufloxacin (TFLX) into the bone and joint tissues of rabbits and its in vitro antibacterial activity were compared with those of lomefloxacin (LFLX) which is a efficacious drug for orthopedic infections. Serum levels of TFLX at 1, 2, 4 and 6 hours after oral administration (100mg/kg) were 0.41, 0.65, 0.62 and 0.42μg/ml, respectively. Except in synovial fluid and femur, TFLX concentrations in bone and joint tissues were higher than those in serum (0.69-1.92μg/g in bone marrow of sternum, 0.55-1.53μg/g in bone marrow of femur). TFLX concentrations in synovial fluid at 4 and 6 hours after the administration were equal to those in serum, which were lower than those of LFLX, but the ratio of tissue level/serum level of TFLX was similar to that of LFLX. TFLX was 8-to 64-fold more active than LFLX against Staphylococcus aureus (including methicillin-resistant S. aureus), Streptococcus pyogenes, Haemophilus influenzae, which are major pathogens of purulent osteomyelitis and arthritis. TFLX inhibited the growth of these bacteria at less than 0.39μg/ml. These results indicate that TFLX is a useful drug for orthopedic infection.